FDA approved Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.
FDA approved Gomekli (mirdametinib), a kinase inhibitor from SpringWorks Therapeutics, for adult and pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection.
The European Commission granted marketing authorization for Removab (catumaxomab), making the drug the only approved drug therapy for malignant ascites for patients living with this debilitating condition across Europe.
Moffitt Cancer Center and 1ST Biotherapeutics are collaborating to accelerating innovative cancer research and clinical development.
A federal judge in Massachusetts on Feb. 10, issued a preliminary restraining order, blocking the Trump administration from enforcing an NIH guidance that would cut the indirect costs paid on NIH grants to a flat rate of 15%.
The web page for the FDA Office of Minority Health and Health Equity is no more. The pages for the NCI Diversity Training and Biomedical Workforce Development Branch and Disparities Research Branch are kaput as well.
Robert F. Kenedy Jr., an antivaccine advocate and President Trump’s MAHA nominee, has cleared a key hurdle to be confirmed as secretary of Health and Human Services.
Isolating science by shutting down communication risks building up silos, stymying scientific innovation and dissemination, and creating a culture that excludes rather than includes.
My entire life I was told to respectfully question anything and everything, because questions equal answers, which provide understanding and thereby comfort—even with the uncomfortable. It’s simply in my DNA.
As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).
